Natalizumab plus interferon beta-1a reduces lesion formation in relapsing multiple sclerosis

Ernst-Wilhelm Radue, William H Stuart, Peter A Calabresi, Christian Confavreux, Steven L Galetta, Richard A Rudick, Fred D Lublin, Bianca Weinstock-Guttman, Daniel R Wynn, Elizabeth Fisher, Athina Papadopoulou, Frances Lynn, Michael A Panzara, Alfred W Sandrock, SENTINEL Investigators, Per Soelberg Sørensen, Morten Bjørn Blinkenberg

50 Citationer (Scopus)


The SENTINEL study showed that the addition of natalizumab improved outcomes for patients with relapsing multiple sclerosis (MS) who had experienced disease activity while receiving interferon beta-1a (IFNbeta-1a) alone. Previously unreported secondary and tertiary magnetic resonance imaging (MRI) measures are presented here. Patients received natalizumab 300 mg (n=589) or placebo (n=582) intravenously every 4 weeks plus IFNbeta-1a 30 microg intramuscularly once weekly. Annual MRI scans allowed comparison of a range of MRI end points versus baseline. Over 2 years, 67% of patients receiving natalizumab plus IFNbeta-1a remained free of new or enlarging T2-lesions compared with 30% of patients receiving IFNbeta-1a alone. The mean change from baseline in T2 lesion volume over 2 years decreased in patients receiving natalizumab plus IFNbeta-1a and increased in those receiving IFNbeta-1a alone (-277.5mm(3) versus 525.6mm(3); p
TidsskriftJournal of the Neurological Sciences
Udgave nummer1-2
Sider (fra-til)28-35
Antal sider8
StatusUdgivet - 15 maj 2010


Dyk ned i forskningsemnerne om 'Natalizumab plus interferon beta-1a reduces lesion formation in relapsing multiple sclerosis'. Sammen danner de et unikt fingeraftryk.